Barclays PLC Purchases 46,997 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS)

Barclays PLC increased its position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 275.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 64,089 shares of the company’s stock after buying an additional 46,997 shares during the quarter. Barclays PLC owned 0.11% of Pyxis Oncology worth $235,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. MetLife Investment Management LLC grew its stake in shares of Pyxis Oncology by 41.1% during the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after acquiring an additional 5,484 shares in the last quarter. Pier 88 Investment Partners LLC boosted its holdings in Pyxis Oncology by 7.0% during the third quarter. Pier 88 Investment Partners LLC now owns 121,610 shares of the company’s stock worth $446,000 after purchasing an additional 7,910 shares during the last quarter. Jane Street Group LLC grew its position in Pyxis Oncology by 40.8% in the third quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock valued at $182,000 after purchasing an additional 14,349 shares in the last quarter. Intech Investment Management LLC acquired a new stake in Pyxis Oncology in the 3rd quarter valued at $55,000. Finally, SG Americas Securities LLC bought a new stake in Pyxis Oncology during the 3rd quarter worth about $58,000. Institutional investors and hedge funds own 39.09% of the company’s stock.

Insider Transactions at Pyxis Oncology

In other news, CFO Pamela Ann Connealy acquired 88,850 shares of the stock in a transaction on Tuesday, November 26th. The shares were purchased at an average price of $1.96 per share, for a total transaction of $174,146.00. Following the transaction, the chief financial officer now directly owns 1,199,143 shares of the company’s stock, valued at approximately $2,350,320.28. This represents a 8.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 9.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

PYXS has been the topic of a number of recent research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 target price (down previously from $10.00) on shares of Pyxis Oncology in a research report on Friday, December 20th. Stephens began coverage on Pyxis Oncology in a research note on Friday, November 8th. They set an “overweight” rating and a $13.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective (down previously from $7.00) on shares of Pyxis Oncology in a report on Friday, December 20th. Finally, William Blair downgraded shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $9.43.

Pyxis Oncology Price Performance

Shares of Pyxis Oncology stock opened at $1.50 on Tuesday. The business has a fifty day simple moving average of $2.09 and a two-hundred day simple moving average of $3.03. Pyxis Oncology, Inc. has a 1 year low of $1.39 and a 1 year high of $6.85. The company has a market capitalization of $89.21 million, a price-to-earnings ratio of -1.46 and a beta of 1.06.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.